Sionna Therapeutics

Sionna Therapeutics, founded in 2018 and headquartered in the United States, is a groundbreaking life sciences company dedicated to delivering therapies that could be transformational for people living with cystic fibrosis. Their mission is reflected in their slogan, "Dedicated to delivering therapies that could be transformational for people living with cystic fibrosis." The company is focused on developing first-in-class small molecules that target the genetic mutations associated with cystic fibrosis. This approach has the potential to fully normalize CFTR function for the vast majority of people living with CF. Sionna Therapeutics is operating in the Biotechnology, Health Care, and Pharmaceutical industries, making their innovative research and development critical for the future of cystic fibrosis treatment. Sionna Therapeutics' progress is evident from their recent Series C investment of $182.00M on 06 March 2024. Notable investors in this round include Atlas Venture, RA Capital Management, OrbiMed, The Rise Fund, T. Rowe Price, Cystic Fibrosis Foundation, Enavate Sciences, Perceptive Advisors, Viking Global Investors, and Q Healthcare Holdings. Overall, Sionna Therapeutics' groundbreaking approach and recent substantial investment signify the potential for significant advancements in cystic fibrosis treatment, making it a compelling opportunity for venture capital investment.